ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

HIK Hikma Pharmaceuticals Plc

1,799.00
10.00 (0.56%)
19 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Hikma Pharmaceuticals Plc LSE:HIK London Ordinary Share GB00B0LCW083 ORD SHS 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  10.00 0.56% 1,799.00 1,805.00 1,807.00 1,807.00 1,763.00 1,786.00 466,727 16:35:19
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 2.88B 192M 0.8685 20.78 3.99B
Hikma Pharmaceuticals Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker HIK. The last closing price for Hikma Pharmaceuticals was 1,789p. Over the last year, Hikma Pharmaceuticals shares have traded in a share price range of 1,711.00p to 2,222.00p.

Hikma Pharmaceuticals currently has 221,081,676 shares in issue. The market capitalisation of Hikma Pharmaceuticals is £3.99 billion. Hikma Pharmaceuticals has a price to earnings ratio (PE ratio) of 20.78.

Hikma Pharmaceuticals Share Discussion Threads

Showing 1026 to 1048 of 1875 messages
Chat Pages: Latest  51  50  49  48  47  46  45  44  43  42  41  40  Older
DateSubjectAuthorDiscuss
15/8/2018
07:38
Our performance in the first half exceeded our expectations and we are pleased to be able to raise our guidance for both our Injectables and Generics businesses for the full year.
broadwood
15/8/2018
07:17
Results far and away better than expected.

Been accumulating (selling peaks buying troughs) for a while. Holding tight now for the time being.

£20ps a likely possibility imo.

imho, dyor etc etc

bantam175
15/8/2018
07:06
Wish I'd bought more when under a tenner. Hindsight...
richtea2517
14/8/2018
22:58
Should prove how wrong was Numis.
karateboy
14/8/2018
21:46
wonder what tomorrow will bring
eentweedrie
13/8/2018
19:21
A few decent buys at the close hope they haven't had the nod
joshuam
10/8/2018
10:16
I like Hikma long term but I don't hold any stock through results after a few bitter experiences where stops have been useless. So I'll sell next week and re buy when I see the right chart spot. If I miss a big rise on results day - es la vida!
jgoold
09/8/2018
12:50
Interims next wednesday will send us off with the correct information. After a rocky period the Company now seems more focused on what it is doing and the share price believes it is doing it well.
chrisgail
07/8/2018
14:00
£17 breached - what a roller coaster but pleased I stayed with it.
Suet

suetballs
01/8/2018
07:07
I agree . Next stop is £20.
karateboy
01/8/2018
00:01
Agree....I still think HIK will head back up to £20 .....by end of the year ...imo
gerrym two
31/7/2018
19:34
Very strange trading pattern today. Shares drops lunch time to negative territory, then picks up at 15:00 to 1660p and closes at 1641p. Let's see if there is an RNS tomorrow.
karateboy
20/7/2018
08:30
Upward trend for past 3 months since Teva chap and co. Joined
r ball
20/7/2018
08:20
up almost 10% in a few days!
eentweedrie
19/7/2018
20:15
We may be on the way to £20 having finally broken back of £15.!
karateboy
19/7/2018
14:46
Won't hurt HIK to have a few brownie points with the FDA either.
bantam175
19/7/2018
12:53
I suppose this is what a drug shortage does....
r ball
09/7/2018
09:51
Someone is after our shares hold firm
joshuam
01/6/2018
05:56
The main factor here is Indian drug manufacturers, and FDA.If you don't understand this you should not be invested.
r ball
30/5/2018
16:31
Not a related issue imo.
bantam175
30/5/2018
10:26
RNS:
"London, 30 May 2018 - Hikma Pharmaceuticals PLC (Hikma, Group) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1 Moody's / BB+ S&P, both stable) announces that its wholly-owned US subsidiary, West-Ward Pharmaceuticals Corp. (West-Ward), has launched Methylergonovine Maleate Tablets, USP, 0.2mg, the generic equivalent to Methergine(R) .(1)

Methylergonovine Maleate Tablets are a semi-synthetic ergot alkaloid used for the prevention and control of postpartum hemorrhage."
-----------------

Why on earth this has caused the share price to tank is just beyond me...
j

jswjsw
25/5/2018
10:11
Starting to move up !
gerrym two
23/5/2018
16:28
Cheers for the encouragement, almost back to yesterday at end of the day.
vas007
Chat Pages: Latest  51  50  49  48  47  46  45  44  43  42  41  40  Older

Your Recent History

Delayed Upgrade Clock